![]() ![]() Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS) Curr Med Res Opin. doi: 10.1016/j.anai.2017.09.076.įoley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Burden of skin pain in atopic dermatitis. Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. Ĭhopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Atopic dermatitis: global epidemiology and risk factors. These severity strata provide score interpretations of the WP-NRS, ADerm-SS, and ADerm-IS, translating these scores to simple and intuitive outcomes, which can inform clinical studies and clinical practice.ĪDerm-IS ADerm-SS Atopic dermatitis Patient-reported outcomes Pruritus Severity strata Skin pain Sleep. For ADerm-IS Emotional State, 0 was associated with absent, 1-2 with minimal, 3-8 with mild, 9-22 with moderate, and 23-30 with severe. The sealed control panel and rounded design make the scale. For ADerm-IS Daily Activities, 0 was associated with absent, 1-2 with minimal, 3-7 with mild, 8-25 with moderate, and 26-40 with severe. Escali Primo Digital Scales are multifunctional and feature an easy to use two-button operation. For ADerm-IS Sleep, 0 was associated with absent, 1-3 with minimal, 4-6 with mild, 7-20 with moderate, and 21-30 with severe. For ADerm-SS 7-Item Total Symptom Score (TSS-7), 0-1 was associated with absent, 2-11 with minimal, 12-22 with mild, 23-47 with moderate, and 48-70 with severe. For the ADerm-SS Skin Pain, 0 was associated with absent, 1 with minimal, 2 with mild, 3-6 with moderate, and 7-10 with severe. For the WP-NRS, 0 was associated with absent, 1-2 with minimal, 3 with mild, 4-7 with moderate, and 8-10 with severe. The sample included 769 adults and 113 adolescents. Analyses were conducted separately for adults and adolescents, and then harmonized between the two age groups. Using data from a global, randomized, double-blind, placebo-controlled, phase 3 clinical trial ( NCT03568318) of patients with moderate-severe AD (age ≥ 12 years), equipercentile linking analyses were conducted to define severity strata applying the Patient Global Impression of Severity as an anchor. Severity strata for these PROs are needed to aid in their interpretation. Three patient-reported outcome (PRO) questionnaires-Worst Pruritus Numerical Rating Scale (WP-NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)-were developed to assess the symptoms and impacts of atopic dermatitis (AD).
0 Comments
Leave a Reply. |